Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population

<b>Background:</b> Achieving low disease activity or remission in psoriatic arthritis (PsA) remains difficult. The GRAPPA group recently defined difficult-to-treat (D2T) PsA but did not include a time-based criterion. <b>Objectives:</b> This study aimed to evaluate the prevalence and features of D2T PsA using several operational definitions. <b>Methods:</b> A cross-sectional study at a tertiary center enrolled PsA patients with active disease confirmed by clinical exam and ultrasound. D2T PsA was defined by: (1) failure of ≥1 csDMARD plus ≥2 b/tsDMARDs with different mechanisms of action (GRAPPA definition); (2) ≥2 b/tsDMARDs with different mechanisms of action within 12 months (time-based definition); or (3) failure of >3 b/tsDMARDs with different mechanisms of action (very refractory). Clinical, demographic, radiographic, and ultrasound data were analyzed, and multivariable analyses identified independent associations. <b>Results:</b> Seventy-two patients (54.2% female, median age 56, disease duration 84 months) all had active disease (median DAPSA 17); 68% had comorbidities. Enthesitis, dactylitis, and nail disease were seen in 20.8%, 45.8%, and 41.7%. HLA-B27 positivity was 13.9%. Radiographic erosions and ultrasound paratenonitis were present in 37.5% and 33.3%. GRAPPA D2T criteria were met by 23.6%, linked to longer disease duration, higher activity, HLA-B27, comorbidities, and combined therapy. Time-based D2T (12.5%) showed higher DAPSA and nail involvement, with ultrasound paratenonitis and combined therapy independently associated. Very refractory patients (11.1%) only correlated with combined therapy. <b>Conclusions:</b> Up to one-fourth of PsA patients remain active despite multiple treatments. D2T PsA is associated with disease duration, comorbidities, activity, HLA-B27, combined therapies. Remarkably, patients who fulfilled the <12-month D2T definition were more likely to present with nail involvement and ultrasound-detected paratenonitis.

Authors

Institutions

Publication Details

Journal
Diagnostics
Published
2025-09-23
DOI
https://doi.org/10.3390/diagnostics15192418
Citations
1
Primary Topic
Spondyloarthritis Studies and Treatments
Type
article
Field-Weighted Citation Impact
1.67
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population

Juan D. Cañete, José A. Gómez‐Puerta, Julio Ramírez, Andrés Ponce et al.
1 citations
Diagnostics
Spondyloarthritis Studies and Treatments
1.67
article

Clinical and Ultrasound Characteristics of a Difficult-to-Treat Psoriatic Arthritis Population

Juan D. Cañete, José A. Gómez‐Puerta, Julio Ramírez, Andrés Ponce, Ana Belén Azuaga-Piñango, Joshua Peñafiel‐Sam, Juan Camilo Sarmiento-Monroy, Claudia P. Arango, L. Alascio, Beatriz Frade‐Sosa, O. Omaña, Georgina Novell
article en
1 citations

Abstract

<b>Background:</b> Achieving low disease activity or remission in psoriatic arthritis (PsA) remains difficult. The GRAPPA group recently defined difficult-to-treat (D2T) PsA but did not include a time-based criterion. <b>Objectives:</b> This study aimed to evaluate the prevalence and features of D2T PsA using several operational definitions. <b>Methods:</b> A cross-sectional study at a tertiary center enrolled PsA patients with active disease confirmed by clinical exam and ultrasound. D2T PsA was defined by: (1) failure of ≥1 csDMARD plus ≥2 b/tsDMARDs with different mechanisms of action (GRAPPA definition); (2) ≥2 b/tsDMARDs with different mechanisms of action within 12 months (time-based definition); or (3) failure of >3 b/tsDMARDs with different mechanisms of action (very refractory). Clinical, demographic, radiographic, and ultrasound data were analyzed, and multivariable analyses identified independent associations. <b>Results:</b> Seventy-two patients (54.2% female, median age 56, disease duration 84 months) all had active disease (median DAPSA 17); 68% had comorbidities. Enthesitis, dactylitis, and nail disease were seen in 20.8%, 45.8%, and 41.7%. HLA-B27 positivity was 13.9%. Radiographic erosions and ultrasound paratenonitis were present in 37.5% and 33.3%. GRAPPA D2T criteria were met by 23.6%, linked to longer disease duration, higher activity, HLA-B27, comorbidities, and combined therapy. Time-based D2T (12.5%) showed higher DAPSA and nail involvement, with ultrasound paratenonitis and combined therapy independently associated. Very refractory patients (11.1%) only correlated with combined therapy. <b>Conclusions:</b> Up to one-fourth of PsA patients remain active despite multiple treatments. D2T PsA is associated with disease duration, comorbidities, activity, HLA-B27, combined therapies. Remarkably, patients who fulfilled the <12-month D2T definition were more likely to present with nail involvement and ultrasound-detected paratenonitis.

DiagnosticsVol. 15(19)
Hospital Clínic de Barcelona (ES), Universitat de Barcelona (ES)
Openalex Percentile: Top 13%
Spondyloarthritis Studies and Treatments
1.67
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.